Nuveen’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $23.2M | Buy |
693,959
+31,905
| +5% | +$792K | 0.01% | 1172 |
|
|
2026
Q1 | $13.9M | Sell |
662,054
-139,419
| -17% | -$3.14M | ﹤0.01% | 1361 |
|
|
2025
Q4 | $18.4M | Buy |
801,473
+119,329
| +17% | +$3.92M | ﹤0.01% | 1193 |
|
|
2025
Q3 | $20.5M | Buy |
682,144
+176,992
| +35% | +$5.31M | 0.01% | 1130 |
|
|
2025
Q2 | $18.4M | Sell |
505,152
-13,391
| -3% | -$483K | 0.01% | 1155 |
|
|
2025
Q1 | $18.8M | Buy |
518,543
+129,882
| +33% | +$5.4M | 0.01% | 1161 |
|
|
2024
Q4 | $16.4M | Sell |
388,661
-4,099
| -1% | -$203K | ﹤0.01% | 1300 |
|
|
2024
Q3 | $21.8M | Buy |
392,760
+188,537
| +92% | +$9.6M | 0.01% | 1135 |
|
|
2024
Q2 | $8.39M | Sell |
204,223
-159,144
| -44% | -$6.8M | ﹤0.01% | 1689 |
|
|
2024
Q1 | $17M | Sell |
363,367
-94,080
| -21% | -$4.44M | 0.01% | 1277 |
|
|
2023
Q4 | $21.9M | Buy |
457,447
+26,775
| +6% | +$1.04M | 0.01% | 1093 |
|
|
2023
Q3 | $15.4M | Sell |
430,672
-1,018
| -0.2% | -$40.3K | 0.01% | 1205 |
|
|
2023
Q2 | $19.9M | Sell |
431,690
-19,728
| -4% | -$915K | 0.01% | 1066 |
|
|
2023
Q1 | $18.1M | Sell |
451,418
-12,951
| -3% | -$556K | 0.01% | 1110 |
|
|
2022
Q4 | $21.5M | Buy |
464,369
+260,212
| +127% | +$10.2M | 0.01% | 990 |
|
|
2022
Q3 | $8.45M | Buy |
204,157
+3,874
| +2% | +$199K | ﹤0.01% | 1587 |
|
|
2022
Q2 | $11.9M | Sell |
200,283
-57,862
| -22% | -$3.56M | ﹤0.01% | 1397 |
|
|
2022
Q1 | $17.8M | Buy |
258,145
+1,690
| +0.7% | +$118K | 0.01% | 1261 |
|
|
2021
Q4 | $21.6M | Sell |
256,455
-44,070
| -15% | -$3.59M | 0.01% | 1187 |
|
|
2021
Q3 | $27.1M | Buy |
300,525
+13,568
| +5% | +$1.23M | 0.01% | 1060 |
|
|
2021
Q2 | $27.4M | Sell |
286,957
-82,675
| -22% | -$8.61M | 0.01% | 1132 |
|
|
2021
Q1 | $42.1M | Sell |
369,632
-28,791
| -7% | -$3.92M | 0.01% | 813 |
|
|
2020
Q4 | $55.2M | Buy |
398,423
+14,017
| +4% | +$1.66M | 0.02% | 647 |
|
|
2020
Q3 | $31.6M | Sell |
384,406
-50,157
| -12% | -$4.16M | 0.01% | 798 |
|
|
2020
Q2 | $34M | Buy |
434,563
+103,472
| +31% | +$6.85M | 0.01% | 723 |
|
|
2020
Q1 | $14.7M | Buy |
331,091
+28,322
| +9% | +$1.47M | 0.01% | 1066 |
|
|
2019
Q4 | $12.9M | Buy |
302,769
+29,383
| +11% | +$1.21M | ﹤0.01% | 1435 |
|
|
2019
Q3 | $11.7M | Sell |
273,386
-1,695
| -0.6% | -$92.1K | ﹤0.01% | 1466 |
|
|
2019
Q2 | $17.5M | Buy |
275,081
+270,742
| +6,240% | +$17.2M | 0.01% | 1237 |
|
|
2019
Q1 | $301K | Buy |
+4,339
| New | +$248K | ﹤0.01% | 933 |
|
|
2017
Q3 | – | Sell |
-19,439
| Closed | -$1.21M | – | 1149 |
|
|
2017
Q2 | $1.21M | Buy |
19,439
+8,090
| +71% | +$487K | 0.01% | 712 |
|
|
2017
Q1 | $769K | Sell |
11,349
-3,368
| -23% | -$257K | ﹤0.01% | 1050 |
|
|
2016
Q4 | $1.03M | Sell |
14,717
-6,066
| -29% | -$430K | 0.01% | 1139 |
|
|
2016
Q3 | $1.47M | Sell |
20,783
-1,896
| -8% | -$121K | 0.01% | 914 |
|
|
2016
Q2 | $1.11M | Buy |
22,679
+5,331
| +31% | +$345K | 0.01% | 995 |
|
|
2016
Q1 | $1.1M | Sell |
17,348
-3,233
| -16% | -$212K | 0.01% | 989 |
|
|
2015
Q4 | $2.31M | Sell |
20,581
-1,133
| -5% | -$113K | 0.01% | 716 |
|
|
2015
Q3 | $2.09M | Buy |
21,714
+554
| +3% | +$63.4K | 0.01% | 745 |
|
|
2015
Q2 | $2.17M | Buy |
+21,160
| New | +$1.64M | 0.01% | 792 |
|
Other funds holding RARE
RI
FCM
Nuveen's RARE Position: Q2 2026 in Review
Nuveen increased its Ultragenyx Pharmaceutical (RARE) stake by 4.8% in Q2 2026, buying an estimated $792K and bringing the position to 693,959 shares worth $23.2M. The position accounts for 0.01% of the portfolio, ranked #1172.
Nuveen first reported a position in RARE in Q2 2015 and has held it in 39 quarters since. The position peaked at $55.2M in Q4 2020. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- Nuveen held 693,959 shares of Ultragenyx Pharmaceutical worth $23.2M as of Q2 2026.
- Nuveen bought 31,905 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $792K.
- Ultragenyx Pharmaceutical made up 0.01% of Nuveen's portfolio in Q2 2026, its #1172 holding.
- Nuveen first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and has held it in 39 quarters since.
- Nuveen's Ultragenyx Pharmaceutical position peaked at $55.2M in Q4 2020.
- 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.